Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cumberland Pharmaceu (CPIX)

Cumberland Pharmaceu (CPIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cumberland Pharmaceu 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203 USA

www.cumberlandpharma.com Employees: 93 P: 615-255-0068 F: 615-255-0094

Sector:

Medical

Description:

Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.

Key Statistics

Overview:

Market Capitalization, $K 45,918
Enterprise Value, $K 39,718
Shares Outstanding, K 14,957
Float, K 8,665
% Float 57.93%
Short Interest, K 143
Short Float 0.95%
Days to Cover 1.00
Short Volume Ratio 0.39
% of Insider Shareholders 42.07%
% of Institutional Shareholders 15.51%

Financials:

Annual Sales, $ 44,520 K
Annual Net Income, $ -2,840 K
Last Quarter Sales, $ 13,680 K
Last Quarter Net Income, $ -1,410 K
EBIT, $ 1,240 K
EBITDA, $ 5,390 K

Growth:

1-Year Return -29.25%
3-Year Return 57.44%
5-Year Return 0.00%
5-Year Revenue Growth 18.91%
5-Year Earnings Growth 216.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 03/03/26
Next Earnings Date 05/05/26
Earnings Per Share ttm 0.09
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 33.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CPIX Ratios

Ratio
Price/Earnings ttm 36.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 5.04%
Return-on-Assets % 1.91%
Profit Margin % -6.38%
Debt/Equity 0.21
Price/Sales 1.09
Price/Cash Flow 8.83
Price/Book 1.97
Book Value/Share 1.64
Interest Coverage -4.62
60-Month Beta -0.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.